Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 03 Feb 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views on the competitiveness of the European pharmaceutical sector. | — |
| 03 Feb 2026 | Carmen Laplaza Santos Head of Unit | Exchange of views on the competitiveness of the European pharmaceutical sector. | SRC |
| 21 Jan 2026 | Laszlo Kristoffy Cabinet member | Health Package | SRC |
| 21 Jan 2026 | Olivér Várhelyi Commissioner | Health Package | SRC |
| 21 Jan 2026 | Olivér Várhelyi Commissioner | Health Package | — |
| 21 Jan 2026 | Laszlo Kristoffy Cabinet member | Health Package | — |
| 02 Dec 2025 | Olivér Várhelyi Commissioner | Pharma affairs | SRC |
| 02 Dec 2025 | Olivér Várhelyi Commissioner | Pharma affairs | — |
| 02 Oct 2025 | Jana Dabbelt Cabinet member | All pressing portfolio topics | SRC |
| 02 Oct 2025 | Olivér Várhelyi Commissioner | All pressing portfolio topics | SRC |
| 02 Oct 2025 | Jana Dabbelt Cabinet member | All pressing portfolio topics | — |
| 17 Sept 2025 | Vincenzo Matano Cabinet member | Introductory Meeting on Coalizione VITA Activities | — |
| 17 Sept 2025 | Vincenzo Matano Cabinet member | Introductory Meeting on Coalizione VITA Activities | SRC |
| 04 Sept 2025 | Vilija Sysaite Cabinet member | European competitiveness aspects | SRC |
| 04 Sept 2025 | Vilija Sysaite Cabinet member | European competitiveness aspects | — |
| 03 Jun 2025 | Maya Matthews Head of Unit | The role of the Commission was here to facilitate the exchange between Novartis and the HTA Coordination Group Chairs about a medicinal product sent for joint clinical assessment | — |
| 03 Jun 2025 | Maya Matthews Head of Unit | The role of the Commission was here to facilitate the exchange between Novartis and the HTA Coordination Group Chairs about a medicinal product sent for joint clinical assessment | SRC |
| 26 May 2025 | Bernardus Zuijdendorp Head of Unit | Exchange of views on the need and prospects for simplification in Pillar 2, in particular in light of the current situation with the US | — |
| 26 May 2025 | Katarina Koszeghy Cabinet member | Exchange of views on the need and prospects for simplification in Pillar 2, in particular in light of the current situation with the US | — |
| 26 May 2025 | Katarina Koszeghy Cabinet member | Exchange of views on the need and prospects for simplification in Pillar 2, in particular in light of the current situation with the US | SRC |
| 26 May 2025 | Bernardus Zuijdendorp Head of Unit | Exchange of views on the need and prospects for simplification in Pillar 2, in particular in light of the current situation with the US | SRC |
| 13 May 2025 | Laurent Muschel Director | Bilateral meeting between Novartis and HERA on international coordination, legislation, innovation | — |
| 13 May 2025 | Laurent Muschel Director | Bilateral meeting between Novartis and HERA on international coordination, legislation, innovation | SRC |
| 11 Apr 2025 | Hoa-Binh Adjemian Head of Unit | Engagement regarding Novartis activities in Serbia and signature of an MoU with the Serbian Government | — |
| 11 Apr 2025 | Hoa-Binh Adjemian Head of Unit | Engagement regarding Novartis activities in Serbia and signature of an MoU with the Serbian Government | SRC |
Mission & Goals
Bringing breakthroughs to more patients At Novartis, we don’t just discover life-changing medicines, we're part of a broader effort to help ensure medicines reach the people who need them most, wherever they live, because the true value of innovation lies in its ability to improve lives. Ensuring people everywhere can benefit from the latest medical breakthroughs is a shared global responsibility – one we care deeply about and work hard to uphold through our science, value and access initiatives, and government and community partnerships. Yet, this shared responsibility has grown out of balance, with a disproportionate burden placed on certain countries and even patients. Our mission is simple: push the boundaries of science and ensure every breakthrough reaches those who need it fairly, affordably, and without delay because every patient deserves a future shaped by innovation. https://www.novartis.com/news/bringing-breakthroughs-more-patients
EU Legislative Interests
ATMP Regulation, Big data, Biosimilars & generics, Clinical Trials Regulation, Data Protection Regulation, EU IP policy, EU Relative Efficacy Assessment , EU research policy, EU trade policy, Health Systems Performance Assessment, Health Technology Assessment & Market Access, Industrial policy, IHI, Outcomes-based healthcare systems, Orphan Medicinal Products Regulation, Paediatric Regulation, Patient access to innovation, Patient safety, Pharmaceuticals in the environment, Sustainable Development Goals, Corporate Sustainability Due Diligence Directive, Corporate Sustainability Reporting Directive , General Pharmaceutical Legislation, Critical Medicines Act, EU Mercury Regulation, urban Waste Water Treatment Directive, Artificial intelligence, European Health Data Space, Life Science Strategy, Biotech Act, PFAS, EU Mercury Regulation, INI beating Cancer plan
Communication Activities
Stakeholder event - Sustainable Livelihoods Summit Friends of Europe 4-5 June 2025 Stakeholder event - 7th Strasbourg Lunch Debate - 9 July 2025 - The Critical Medicines Act and its implications for health and geopolitics at the European level and beyond Stakeholder event - Science Business 14 Oct 2025 EUCOPE Environmental Roundtable 4th December 2025 Advancing Radioligand Therapies (RLT) in Europe - Working Breakfast at the European Parliament on 24 Sept - Jointed event with NV Spain and NV Italy - amount covered by Brussels Office EFPIA CVD Workstream EFPIA Oncology Platform EFPIA Irish Court Case EPF High level policy event European Access Academy European Kidney Health Alliance (EKHA) EURORDIS - Round Table of Companies Nuclear Medicine Europe (NMEU) 2x FH Europe Events Lp(a) Global Summit + EP Event EHS European Health Summit 2/3d December 2025 with Patrick Horber
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Business Europe Membership Critical Medicines Alliance ECPA EFPIA - Pillar 3 IMI EFPIA (Pillar 1+2) EFPIA: Pillar 3 ICH EFPIA Country engagement EFPIA Campaign mode EFPIA - Contribution to Fairer pharmaceutical spending & improved industrial ecosystem in Europe 'advocacy 1 communication plan 2025' Eucope (Membership) Eucope Membership - Support to the incentive Steering Group (ISG) Eucope Membership (OLU WG) Eucope Membership (Pricing & Reimb./Market Access WG) EuropaBio EuropeanIssuers European Cancer Organisation (ECO) Friends of Europe Kangaroo Medtech Europe Science Business EU Matrix EBS Membership SPARC Europe EFPIA CVD Workstream EFPIA Oncology Platform EPF Annual Plan European Access Academy European Kidney Health Alliance (EKHA) EURORDIS - Round Table of Companies DGA - TBCT membership Nuclear Medicine Europe (NMEU)
Organisation Members
We do not have members
Additional Information
We have calculated the estimate of annual costs related to activities covered by the register by adding our membership fees, event and project costs, consultancy fees together with facilities (rental charges) and personal costs.
Connected Legislation